Mizuho analyst Anthony Crowdell maintains Duke Energy (NYSE:DUK) with a Neutral and raises the price target from $100 to $102.
Andelyn Biosciences Selected By Ultragenyx For Late-Stage Process Performance Qualification Manufacturing Of Novel Gene Therapy For Sanfilippo Syndrome
Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), announced that it has been selected by Ultragenyx (NASDAQ:RARE) to